TY - JOUR
T1 - Ranking microbiome variance in inflammatory bowel disease
T2 - A large longitudinal intercontinental study
AU - Clooney, Adam G.
AU - Eckenberger, Julia
AU - Laserna-Mendieta, Emilio
AU - Sexton, Kathryn A.
AU - Bernstein, Matthew T.
AU - Vagianos, Kathy
AU - Sargent, Michael
AU - Ryan, Feargal J.
AU - Moran, Carthage
AU - Sheehan, Donal
AU - Sleator, Roy D.
AU - Targownik, Laura E.
AU - Bernstein, Charles N.
AU - Shanahan, Fergus
AU - Claesson, Marcus J.
PY - 2021/3
Y1 - 2021/3
N2 - Objective The microbiome contributes to the pathogenesis of inflammatory bowel disease (IBD) but the relative contribution of different lifestyle and environmental factors to the compositional variability of the gut microbiota is unclear. Design Here, we rank the size effect of disease activity, medications, diet and geographic location of the faecal microbiota composition (16S rRNA gene sequencing) in patients with Crohn's disease (CD; n=303), ulcerative colitis (UC; n = 228) and controls (n=161), followed longitudinally (at three time points with 16 weeks intervals). Results Reduced microbiota diversity but increased variability was confirmed in CD and UC compared with controls. Significant compositional differences between diseases, particularly CD, and controls were evident. Longitudinal analyses revealed reduced temporal microbiota stability in IBD, particularly in patients with changes in disease activity. Machine learning separated disease from controls, and active from inactive disease, when consecutive time points were modelled. Geographic location accounted for most of the microbiota variance, second to the presence or absence of CD, followed by history of surgical resection, alcohol consumption and UC diagnosis, medications and diet with most (90.3%) of the compositional variance stochastic or unexplained. Conclusion The popular concept of precision medicine and rational design of any therapeutic manipulation of the microbiota will have to contend not only with the heterogeneity of the host response, but also with widely differing lifestyles and with much variance still unaccounted for.
AB - Objective The microbiome contributes to the pathogenesis of inflammatory bowel disease (IBD) but the relative contribution of different lifestyle and environmental factors to the compositional variability of the gut microbiota is unclear. Design Here, we rank the size effect of disease activity, medications, diet and geographic location of the faecal microbiota composition (16S rRNA gene sequencing) in patients with Crohn's disease (CD; n=303), ulcerative colitis (UC; n = 228) and controls (n=161), followed longitudinally (at three time points with 16 weeks intervals). Results Reduced microbiota diversity but increased variability was confirmed in CD and UC compared with controls. Significant compositional differences between diseases, particularly CD, and controls were evident. Longitudinal analyses revealed reduced temporal microbiota stability in IBD, particularly in patients with changes in disease activity. Machine learning separated disease from controls, and active from inactive disease, when consecutive time points were modelled. Geographic location accounted for most of the microbiota variance, second to the presence or absence of CD, followed by history of surgical resection, alcohol consumption and UC diagnosis, medications and diet with most (90.3%) of the compositional variance stochastic or unexplained. Conclusion The popular concept of precision medicine and rational design of any therapeutic manipulation of the microbiota will have to contend not only with the heterogeneity of the host response, but also with widely differing lifestyles and with much variance still unaccounted for.
KW - colonic microflora
KW - Crohn's disease
KW - diet
KW - ulcerative colitis
KW - microbiome
KW - microbiota
UR - http://www.scopus.com/inward/record.url?scp=85100661270&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2020-321106
DO - 10.1136/gutjnl-2020-321106
M3 - Article
C2 - 32536605
AN - SCOPUS:85100661270
SN - 0017-5749
VL - 70
SP - 499
EP - 510
JO - Gut
JF - Gut
IS - 3
ER -